問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital

Division of General Internal Medicine

Division of Nephrology

更新時間：2025-08-20

陸政鼎
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陸政鼎

List

9Cases

2025-11-01 - 2030-12-31

Phase III

Active
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

  • Condition/Disease

    Focal Segmental Glomerulosclerosis

  • Test Drug

    膜衣錠 膜衣錠

Participate Sites
9Sites

Recruiting9Sites

2025-04-01 - 2029-09-30

Active
A phase 3, randomized, double-blind, placebo-controlled trial (PREVAIL) of Felzartamab in adult patients with IgA nephropathy.

  • Condition/Disease

    The percentage change in proteinuria from baseline to week 36 was assessed based on the urine protein/creatinine ratio (UPCR) measurement of 24-hour urine samples.

  • Test Drug

    Felzartamab

Participate Sites
8Sites

Recruiting8Sites

2024-11-01 - 2028-02-16

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-07-01 - 2030-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-06-13 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-09-30 - 2028-11-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2025-10-15 - 2028-10-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-08-31 - 2029-05-11

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2026-02-01 - 2028-05-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB